Related Experiment Videos
Enhanced drug metabolism in young children with cystic fibrosis
A C Parker1, P Pritchard, T Preston
1Institute of Child Health, Alder Hey Children's Hospital, Liverpool.
Insights
Cystic fibrosis patients show altered caffeine metabolism, indicating enhanced drug metabolism in young children. This suggests a hereditary basis, not linked to lung or liver damage.
Area of Science:
- Pharmacokinetics and Drug Metabolism
- Pediatric Gastroenterology
- Genetic Disorders
Background:
- Cystic fibrosis (CF) is a genetic disorder affecting multiple organs.
- Altered drug metabolism can impact treatment efficacy in CF patients.
- The CYP1A2 enzyme plays a key role in metabolizing various drugs, including caffeine.
Purpose of the Study:
- To investigate the effect of cystic fibrosis on caffeine metabolism in young children.
- To determine if enhanced drug metabolism in CF is hereditary or due to organ damage.
Main Methods:
- Utilized the caffeine breath test in eight children with CF (aged 2-6 years) and nine age-matched controls.
- Measured the cumulative percentage of labeled caffeine exhaled as carbon dioxide over two hours.
Main Results:
- Patients with cystic fibrosis exhibited significantly higher levels of exhaled labeled carbon dioxide compared to controls.
- This suggests an accelerated CYP1A2 metabolic pathway in children with CF.
- The observed effect was present in young children with minimal lung and liver disease.
Conclusions:
- Enhanced caffeine metabolism in young children with cystic fibrosis suggests an inherent, likely hereditary, metabolic difference.
- This finding implies that drug metabolism alterations in CF may not solely be a consequence of lung and liver damage.
- Further research into genetic influences on drug metabolism in CF is warranted.
Abstract:
The effect of cystic fibrosis on caffeine metabolism was studied in young children using the caffeine breath test. Eight children with cystic fibrosis aged 2-6 years and nine age matched controls were studied on a single occasion, and the cumulative percentage of labelled caffeine exhaled as carbon dioxide measured over two hours. This was significantly higher in the patients with cystic fibrosis than in controls, suggesting an increase in the CYP1A2 metabolic pathway in the former. The fact that these were young children with minimal lung and liver disease suggests that enhanced drug metabolism in children with cystic fibrosis is hereditary rather than secondary to lung and liver damage.